Lantheus Holdings, Inc. (NASDAQ:LNTH) Receives Consensus Rating of “Buy” from Analysts

Lantheus Holdings, Inc. (NASDAQ:LNTH) has been assigned a consensus recommendation of “Buy” from the seven brokerages that are presently covering the firm, Marketbeat reports. Seven equities research analysts have rated the stock with a buy rating. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $131.86.

Several brokerages have recently issued reports on LNTH. Truist Financial reiterated a “buy” rating and set a $120.00 price target (down from $135.00) on shares of Lantheus in a report on Friday, November 8th. StockNews.com downgraded Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. JMP Securities cut their price target on Lantheus from $125.00 to $112.00 and set a “market outperform” rating on the stock in a research note on Thursday, November 7th. Finally, The Goldman Sachs Group began coverage on Lantheus in a research note on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price objective for the company.

Institutional Trading of Lantheus

Several institutional investors have recently added to or reduced their stakes in the stock. Reinhart Partners LLC. raised its holdings in Lantheus by 9.9% during the 4th quarter. Reinhart Partners LLC. now owns 1,366,873 shares of the medical equipment provider’s stock worth $122,280,000 after purchasing an additional 123,282 shares during the last quarter. Harbor Capital Advisors Inc. raised its stake in Lantheus by 12.8% during the fourth quarter. Harbor Capital Advisors Inc. now owns 145,379 shares of the medical equipment provider’s stock worth $13,006,000 after buying an additional 16,466 shares during the last quarter. Nordea Investment Management AB lifted its holdings in Lantheus by 4.6% in the fourth quarter. Nordea Investment Management AB now owns 47,042 shares of the medical equipment provider’s stock valued at $4,202,000 after buying an additional 2,072 shares during the period. Everence Capital Management Inc. bought a new stake in Lantheus during the fourth quarter valued at $210,000. Finally, GAMMA Investing LLC grew its holdings in Lantheus by 118.0% during the 4th quarter. GAMMA Investing LLC now owns 1,018 shares of the medical equipment provider’s stock worth $91,000 after acquiring an additional 551 shares during the period. 99.06% of the stock is currently owned by institutional investors.

Lantheus Trading Down 1.3 %

Shares of Lantheus stock opened at $94.65 on Tuesday. The firm has a market capitalization of $6.58 billion, a PE ratio of 15.75 and a beta of 0.46. The firm’s 50 day moving average is $90.39 and its 200 day moving average is $99.69. Lantheus has a 1 year low of $50.20 and a 1 year high of $126.89.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.